Correspondence 0001193125-22-307337 from Vor Biopharma Inc. (VOR)
Vor Biopharma Inc.
Date: Dec. 16, 2022 · CIK: 0001817229 · Accession: 0001193125-22-307337
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268798
Letter
VOR BIOPHARMA INC.
100 Cambridgepark Drive, Suite 101
Cambridge, MA 02140
December 16, 2022
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Jason Drory
Re:
Vor Biopharma Inc.
Registration Statement on Form S-3 (File No. 333-268798)
Request for Acceleration of Effective Date
Acceleration Request
Requested Date: December 20, 2022
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-268798) (the “Registration Statement”) to become effective on December 20, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, Katie Kazem at (703) 456-8043.
[Signature page follows]
Very truly yours,
Vor Biopharma Inc.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
VOR BIOPHARMA INC.
100 Cambridgepark Drive, Suite 101
Cambridge, MA 02140
December 16, 2022
Via EDGAR
U.S. Securities and Exchange
Commission
Division of Corporation Finance
100 F Street,
N.E.
Washington, D.C. 20549
Attn:
Jason Drory
Re:
Vor Biopharma Inc.
Registration Statement on Form S-3 (File No. 333-268798)
Request for Acceleration of Effective Date
Acceleration Request
Requested Date: December 20, 2022
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the
above-referenced Registration Statement on Form S-3 (File No. 333-268798) (the “Registration Statement”) to become effective
on December 20, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared
effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, Katie Kazem at (703)
456-8043.
[Signature page follows]
Very truly yours,
Vor Biopharma Inc.
By:
/s/ Robert Ang
Robert Ang
Chief Executive Officer and Director
cc:
Robert Ang, Vor Biopharma Inc.
Nathan Jorgensen, Vor Biopharma Inc.
Divakar
Gupta, Cooley LLP
Katie Kazem, Cooley LLP
Signature Page to Company Acceleration Request – S-3